All news

A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Recursion Pharmaceuticals, Inc. director Robert Hershberg exercised options for 25,000 Class A common shares at $2.22 per share and subsequently sold those shares at $5.00 per share on October 6, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted in December 2025. After the sale, Hershberg's reported option position covered 500,000 shares with a $2.22 exercise price and a March 19, 2030 expiration date.

Read original source

RXRX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.